Neurocrine Biosciences (NBIX) Set to Release Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of $1.91 per share and revenue of $1.04 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The firm had revenue of $959.00 million for the quarter, compared to the consensus estimate of $891.16 million. During the same period in the prior year, the company posted $1.65 earnings per share. The company’s quarterly revenue was up 39.5% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $7.72 EPS for the current fiscal year and $9.28 EPS for the next fiscal year.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $146.10 on Friday. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The business’s 50-day moving average is $146.63 and its two-hundred day moving average is $147.39. The company has a market cap of $14.85 billion, a price-to-earnings ratio of 21.42, a P/E/G ratio of 0.64 and a beta of 0.40.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. TD Cowen upped their price target on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group lifted their price objective on Neurocrine Biosciences from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Truist Financial lifted their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 14th. Finally, Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $201.14.

Insider Transactions at Neurocrine Biosciences

In other news, insider David W. Boyer sold 826 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the transaction, the insider owned 8,722 shares of the company’s stock, valued at approximately $1,373,278.90. This represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at $6,729,417.60. This represents a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.